NCT04185636View on ClinicalTrials.gov

Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X

UnknownOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Skin Graft (Allograft)(Autograft) Failure
Interventions
DEVICE

MolecuLight i:X imaging

The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.

Trial Locations (1)

B18 7QH

Birmingham City University Hospitals, Birmingham

Sponsors

Lead Sponsor

MolecuLight Inc.
All Listed Sponsors
lead

MolecuLight Inc.

INDUSTRY

NCT04185636 - Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X | Biotech Hunter | Biotech Hunter